J. C. Sharma, L. Macnamara, M. Hasoon, and M. Vassallo, Diagnostic and therapeutic value of apomorphine in Parkinsonian patients, Int J Clin Pract, vol.58, issue.11, pp.1028-1060, 2004.

A. Antonini, Apomorphine and levodopa infusion therapies for advanced Parkinson's disease, J Mov Disord, vol.2, issue.1, pp.4-9, 2009.

K. Chaudhuri, A. Rizos, and K. D. Sethi, Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?, J Neural Transm

, , vol.120, pp.1305-1325

C. Trenkwalder, C. K. Ray, R. García, P. Lewitt, R. Katzenschlager et al., Expert consensus group report on the use of apomorphine in the treatment of parkinson's diseaseclinical practice recommendations, Parkinsonism Relat Disord, vol.21, issue.9, pp.1023-1053, 2015.

W. A. Emboden, Transcultural use of narcotic water lilies in ancient Egyptian and Maya drug ritual, J Ethnopharmacol, vol.3, issue.1, pp.39-83, 1981.

W. A. Emboden and D. M. De-rios, Mayan-Egyptian uses of water lilies (Nymphaceae) in shamanic ritual drug use, pp.275-86, 1981.

W. A. Emboden, The sacred narcotic lily of the nile: nymphaea caerulea, Econ Bot, vol.32, p.395, 1978.

R. Kandeler and W. R. Ullrich, Symbolism of plants: examples from European-Mediterranean culture presented with biology and history of art, J Exp Bot, vol.60, issue.9, pp.2461-2465, 2009.

P. Taba, A. Lees, and G. Stern, Erich Harnack (1852-1915) and a short history of apomorphine, Eur Neurol, vol.69, issue.6, pp.321-325, 2013.

W. A. Emboden, The mushroom and the water lily: literary and pictorial evidence for Nymphaea as a ritual psychotogen in Mesoamerica, J Ethnopharmacol, vol.5, issue.2, pp.139-187, 1982.

E. Bertol, V. Fineschi, S. B. Karch, F. Mari, and I. Riezzo, Nymphaea cults in ancient Egypt and the New World: a lesson in empirical pharmacology, 12. Stern G. Apolaustic apomorphine. Pract Neurol, vol.97, issue.2, pp.335-342, 2004.

A. Mcdonald and B. Stross, Water lily and cosmic serpent: equivalent conduits of the maya spirit realm, J Ethnobiol, vol.32, issue.1, pp.74-107, 2012.

,

C. Fj, Hallucinogenic drugs in pre-Columbian Mesoamerican cultures, Neurologia, vol.30, issue.1, pp.42-51, 2015.

A. E. Arppe, Ueber eine merkwürdige Veränderung des Morphins durch Schwefelsäure. Liebig's Annalen der Chemie und Pharmacie 1845, p.96

A. Laurent and C. Gerhardt, On sulphomorphide and sulphonarcotide, derivatives from morphia and narcotina (1848) Philosophical, Magazine Series, vol.3, issue.223, pp.396-397

A. Matthiessen, Researches into the constitution of the opium bases. Part II.-On the action of hydrochloric acid on codeia, Proc R Soc Lond, vol.17, pp.460-462

T. Anderson, On the constitution of codeine and its product of decomposition, Trans R Soc Edinb, vol.20, pp.57-86, 1853.

J. Bourgeois and . De-l'apomorphine, recherches cliniques sur un nouvel e ´métique. A. Delahaye (Paris), 1874, pp61 ark:/12148/ bpt6k6138108d

C. David, Contribution a ` l'e ´tude physiologique du chlorhydrate d'apomorphine. L. Vincent (Lausanne), vol.1875

A. Matthiessen and C. Wright, Researches into the chemical constitution of the opium bases. Part I.-On the action of hydrochloric acid on Morphia, Proc R Soc Lond, vol.17, pp.455-460

S. Gee, On the action of a new organic base, apomorphia, Clin Soc Trans, vol.2, pp.166-175, 1869.

A. Matthiessen and W. Burnside, Researches into the chemical constitution of the opium bases. Part IV. On the action of chloride of zinc on codeia, Proc R Soc Lond, vol.19, pp.71-74, 1870.

R. Pschorr, B. Jaeckel, and H. Fecht, U ¨ ber die Constitution des Apomorphins, Ber Dtsch Chem Ges, vol.35, pp.4377-92, 1902.

A. M. Ernst, Relation between the action of dopamine and apomorphine and their O-methylated derivatives upon the CNS, Psychopharmacologia, vol.7, issue.6, pp.391-400, 1965.

A. M. Ernst and P. G. Smelik, Site of action of dopamine and apomorphine on compulsive gnawing behaviour in rats, Experientia, vol.22, issue.12, pp.837-845, 1966.

A. M. Ernst, Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats, Psychopharmacologia, vol.10, issue.4, pp.316-339, 1967.

R. M. Pinder, D. A. Buxton, and D. M. Green, On the dopamine-like action of apomorphine, J Pharm Pharmacol, vol.23, issue.12, pp.995-1001, 1971.

S. Lal, Apomorphine in the evaluation of dopaminergic function in man, Prog Neuropsychopharmacol Biol Psychiatry, vol.12, issue.2-3, pp.117-64, 1988.

J. Giesecke, The absolute configuration of apomorphine, Acta Cryst, vol.33, pp.302-305, 1977.

F. M. Pierce, Notes on apomorphia, Br Med J, vol.1870

J. Y. Dent, Apomorphine in the treatment of anxiety states, with special reference to alcoholism, B J Int, vol.32, pp.65-88, 1934.

E. Harnack, Ueber die Wirkungen des Apomorphins am Säugethier und am Frosch, Arch Exp Pathol Pharmakol, vol.2, pp.254-306, 1874.
DOI : 10.1007/bf01976871

V. Siebert, Untersuchungen u ¨ber die physiologischen Wirkungen des Apomorphin. Inaugural-Dissertation zur Erlangung der Doctorgrades. Dorpat, Druck von Heinrich Laakmann, p.1871

T. Murphy, Report on the use of apomorphia in Sunstroke, Ind Med Gaz, vol.14, issue.11, pp.307-317, 1879.

F. C. Colpaert, V. Bever, W. F. Leysen, and J. E. , Apomorphine: chemistry, pharmacology, biochemistry, Int Rev Neurobiol, vol.19, pp.60705-60714, 1976.
DOI : 10.1016/s0074-7742(08)60705-9

M. I. Levy, B. M. Davis, R. C. Mohs, K. S. Kendler, A. A. Mathé et al., Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses, Arch Gen Psychiatry, vol.41, issue.5, pp.520-524, 1984.
DOI : 10.1001/archpsyc.1984.01790160106014

P. Montastruc, C. Damase-michel, and J. L. Montastruc, Apomorphine potentiates vagal bradycardia, Eur J Pharmacol, vol.166, issue.3, pp.511-515, 1989.
DOI : 10.1016/0014-2999(89)90365-8

C. Amsler, Beiträge zur Pharmakologie des Gehirns. NaunynSchmiedebergs Arch Exp Pathol Pharmakol, vol.97, pp.1-14, 1923.

K. Kuschinsky, In: Naunyn-Schmiedeberg's Archives of Pharmacology; 373, 6; 387-389; Naunyn-Schmiedeberg's Archives of Pharmacology by, An anthology from Naunyn-Schmiedeberg's archives of pharmacology. E. Harnack, vol.2, pp.254-306, 1874.

O. Rampin, N. Jérôme, and C. Suaudeau, Proerectile effects of apomorphine in mice, Life Sci, vol.72, issue.21, pp.2329-2365, 2003.

M. Nymark, Apomorphine provoked stereotypy in the dog, Psychopharmacologia (Berlin), vol.26, pp.361-369, 1972.

M. Goiny and K. Uvnäs-moberg, Effects of dopamine receptor antagonists on gastrin and vomiting responses to apomorphine, Naunyn-Schmiedeberg's Arch Pharmacol, vol.336, p.16, 1987.

J. L. Montastruc, M. E. Llau, J. M. Senard, M. A. Tran, O. Rascol et al., A study of tolerance to apomorphine, Br J Pharmacol, vol.117, issue.5, pp.781-787, 1996.

S. M. Pomerantz, Apomorphine facilities male sexual behavior of rhesus monkeys, Pharmacol Biochem Behav, vol.35, issue.3, p.90304, 1990.

. Chouppe, Quelques recherches sur le mode d'action des vomitifs les plus employés, Lyon Med, vol.XVIII, 1875.

T. Jones, Hypodermic or Subcutaneous Medication, Br Med J, vol.2, pp.581-588, 1291.

G. Pouchet, Leçons de pharmacodynamie et de matière médicale Deuxième série, Hypnotiques (sulfonal, trional, hydrate d'amylène, paraldéhyde, uréthane), O. Doin, 1901.

L. Thumas, Ueber das Brechcentrum und u ¨ber die Wirkung einiger pharmakologischer Mittel auf dasselbe, Virchows Arch, vol.123, pp.44-53, 1891.

H. L. Borison and S. C. Wang, Physiology and pharmacology of vomiting, Pharmacol Rev, vol.5, issue.2, pp.193-230, 1953.

F. Dordoni, Sugli effete dell'associazione morfina-apomorfina nel cane. II. L'apomorfina e l'ipertono da decerebrazione, Boll Soc Ital Boil Sper, vol.24, pp.231-234, 1948.

R. S. Schwab, L. V. Amador, and J. Y. Lettvin, Apomorphine in Parkinson's disease, Trans Am Neurol Assoc, vol.56, pp.251-254, 1951.

A. R. Cools and . Commentary-on, Mode of action of apomorphine and Dexamphetamine on Gnawing compulsion in rats, Psychopharmacology, vol.158, issue.3, pp.316-323, 1967.

N. Andén, A. Rubenson, K. Fuxe, and T. Hökfelt, Evidence for dopamine receptor stimulation by apomorphine, J Pharm Pharmacol, vol.19, pp.627-636, 1967.

U. Ungerstedt, L. L. Butcher, S. G. Butcher, N. E. Andén, and K. Fuxe, Direct chemical stimulation of dopaminergic mechanisms in the neostriatum of the rat, Brain Res, vol.14, issue.2, pp.461-71, 1969.

E. S. Tolosa, Letter: paradoxical suppression of chorea by apomorphine, JAMA, vol.229, issue.12, pp.1579-80, 1974.
DOI : 10.1001/jama.1974.03230500015012

J. Braham, I. Sarova-pinhas, and Y. Goldhammer, Apomorphine in Parkinsonian tremor, Br Med J, vol.3, issue.5725, p.768, 1970.
DOI : 10.1136/bmj.3.5725.768
URL : https://www.bmj.com/content/3/5725/768.1.full.pdf

S. Ribari?, The pharmacological properties and therapeutic use of apomorphine, Molecules, vol.17, issue.5, pp.5289-309, 2012.

M. Auffret, S. Drapier, and M. Vérin, Pharmacological insights into the use of apomorphine in Parkinson's disease: clinical relevance, Clin Drug Investig, 2018.

K. A. Halvorsen and O. Martensen-larsen, Apomorphine revived: fortified, prolonged, and improved therapeutical effect, Int J Addict, vol.13, issue.3, pp.475-84, 1978.
DOI : 10.3109/10826087809045262

B. Costall, R. J. Naylor, and J. L. Neumeyer, Differences in the nature of the stereotyped behaviour induced by aporphine derivatives in the rat and in their actions in extrapyramidal and mesolimbic brain areas, Eur J Pharmacol, vol.31, issue.75, pp.90072-90074, 1975.

T. L. Sourkes and S. Lal, Apomorphine and its relation to dopamine in the nervous system, Advances in Neurochemistry, pp.247-99, 1975.

O. Blin, J. P. Azulay, G. Masson, G. Aubrespy, and G. Serratrice, Apomorphine-induced yawning in migraine patients: enhanced responsiveness, Clin Neuropharmacol, vol.14, issue.1, pp.91-96, 1991.
DOI : 10.1097/00002826-199102000-00008

J. Guardia, M. Casas, G. Prat, J. Trujols, L. Segura et al., The apomorphine test: a biological marker for heroin dependence disorder?, Addict Biol, vol.7, issue.4, pp.421-427, 2002.

M. Casas, J. Guardia, G. Prat, and J. Trujols, The apomorphine test in heroin addicts, Addiction, vol.90, issue.6, pp.831-836, 1995.

J. Guardia, M. Casas, G. Prat, J. Trujols, L. Segura et al., The apomorphine test: a biological marker for heroin dependence disorder?, Addict Biol, vol.7, issue.4, pp.421-427, 2002.
DOI : 10.1080/1355621021000006206

J. P. Frankel, A. Hughes, A. J. Lees, G. M. Stern, and J. M. Walshe, Use of apomorphine to test for dopamine responsiveness in Wilson's disease, Lancet, vol.334, issue.8666, pp.801-803, 1989.

S. Lal, . De-la, C. E. Vega, T. L. Sourkes, and H. G. Friesen, Effect of apomorphine on human-growth-hormone secretion, Lancet, vol.2, issue.7778, p.661, 1972.
DOI : 10.1016/s0140-6736(72)93061-9

F. C. Colpaert, V. Bever, W. F. Leysen, and J. E. , Apomorphine: chemistry, pharmacology, biochemistry, Int Rev Neurobiol, vol.19, pp.225-68, 1976.
DOI : 10.1016/s0074-7742(08)60705-9

F. P. Zemlan, J. Hirschowitz, and D. L. Garver, Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients, Arch Gen Psychiatry, vol.43, issue.12, pp.1162-1169, 1986.

E. Friess, T. Kuempfel, J. Winkelmann, D. Schmid, M. Uhr et al., Increased growth hormone response to apomorphine in Parkinson disease compared with multiple system atrophy, Arch Neurol, vol.58, issue.2, pp.241-247, 2001.
DOI : 10.1001/archneur.58.2.241
URL : https://jamanetwork.com/journals/jamaneurology/articlepdf/778589/NOC00233.pdf

W. Pitchot, M. Hansenne, A. G. Moreno, and M. Ansseau, Growth hormone response to apomorphine in obsessive-compulsive disorder, J Psychiatry Neurosci, vol.21, issue.5, pp.343-348, 1996.

J. D. Proctor, A. N. Chremos, E. F. Evans, and A. J. Wasserman, An apomorphine-induced vomiting model for antiemetic studies in man, J Clin Pharmacol, vol.18, issue.2-3, pp.95-104, 1978.

R. Depoortère, C. Barret-grévoz, L. Bardin, and A. Newman-tancredi, Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds, Eur J Pharmacol, vol.597, issue.1-3, pp.34-42, 2008.

F. R. Dias, L. W. De-matos, S. Mde, F. Carey, R. J. Carrera et al., Opposite effects of low versus high dose haloperidol treatments on spontaneous and apomorphine induced motor behavior: evidence that at a very low dose haloperidol acts as an indirect dopamine agonist, Behav Brain Res, vol.229, issue.1, pp.153-162, 2012.

R. Cerbelaud, Manuel vétérinaire ou Formulaire des medications rationnelles et des remèdes secrets, 1908.

P. Cerbelaud, , p.1290, 1910.

D. D. Cote, D. M. Collins, and F. J. Burczynski, Safety and efficacy of an ocular insert for apomorphine-induced emesis in dogs, Am J Vet Res, vol.69, issue.10, pp.1360-1365, 2008.

H. W. Haggard and L. A. Greenberg, Antidotes for strychnine poisoning, JAMA, vol.98, issue.14, pp.1133-1139, 1932.

D. P. Anderson and . Apomorphia-hydrochloride, Can Med Assoc J, vol.33, issue.1, pp.74-79, 1935.

D. Gold and H. Gold, Apomorphine as an antidote to strychnine poisoning, JAMA, vol.100, issue.20, pp.1589-90, 1933.

W. Murrell, On the action of apomorphine and apocodeine, with reference to their value as expectorants in the treatment of chronic bronchitis, BMJ, vol.1, pp.452-458, 1891.

E. A. Rovenstine and S. G. Hershey, The utility of apomorphine in clinical anesthesia, Anesthesiology, vol.6, pp.574-583, 1945.

D. Parr, Cardiovascular collapse during apomorphine treatment, Br Med J, vol.2, issue.4997, pp.860-862, 1956.

F. Feldman, S. Susselman, and S. E. Barrera, A note on apomorphine as a sedative, Am J Psychiatry, vol.102, pp.403-408, 1945.

J. L. Prevost, Note relative a ` un cas de collapsus inquiétant produit par l'apomorphine. Gazette hebdomadaire de médecine et de chirurgie, pp.20-22

D. M. Bourneville and P. Bricon, Manuel des injections sous-cutanées, p.1885

M. I. Levy, B. M. Davis, R. C. Mohs, K. S. Kendler, A. A. Mathé et al., Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses, Arch Gen Psychiatry, vol.41, issue.5, pp.520-524, 1984.

J. A. Morales-rosado, M. A. Cousin, J. O. Ebbert, and E. W. Klee, A critical review of repurposing apomorphine for smoking cessation, Assay Drug Dev Technol, vol.13, issue.10, pp.612-634, 2015.

T. Verger, De l'emploi de l'apomorphine pour l'extraction des corps e ´trangers de l'oesophage. Bulletin général de thérapeutique médicale et chirurgicale, 1878, pp.254-255

S. A. Visanska, Apomorphine and its uses, Med Rec Weekly J Med Surg, vol.54, pp.15-16, 1898.

D. S. Rausten and M. A. Ochs, Apomorphine-naloxone controlled rapid emesis, J Am Coll Emer, vol.2, issue.1, pp.44-49, 1973.

. Maheu, Empoisonnement par les champignons, Bulletin général de thérapeutique médicale, chirurgicale, obstétricale et pharmaceutique, pp.540-544, 1909.

V. Fitzpatrick, A case of opium-poisoning: recovery, Br Med J, vol.2, issue.1292, p.646, 1885.

. David and . Prag, Med. Wochens, 1900, n°33 in Lyon medical 1902, p.252

W. C. Maclean, A comparison of ipecac syrup and apomorphine in the immediate treatment of ingestion of poisons, J Pediatr, vol.82, issue.1, pp.121-125, 1973.

A. L. Mason, Cerebro-spinal meningitis. Five cases. One, of the fulminant (foudroyant) type, treated by subcutaneous injection of apomorphia, morphine and atropine; recovery. One autopsy, Boston Med Surg J, vol.110, issue.6, pp.121-127, 1184.

W. B. Miller, Apomorphine in ardent fever, BMJ, vol.2, p.1309, 1891.

R. T. White, Apomorphine as an emetic prior to obstetric anesthesia; the prevention of inhaled vomitus, Obstet Gynecol, vol.14, issue.1, pp.111-116, 1959.

J. D. Holdsworth, R. M. Furness, and R. G. Roulston, A comparison of apomorphine and stomach tubes for emptying the stomach before general anaesthesia in obstetrics, Br J Anaesth, vol.46, issue.7, pp.526-535, 1974.

J. D. Holdsworth, The place of apomorphine prior to obstetric analgesia, J Int Med Res, vol.6, issue.1, pp.26-32, 1978.

O. Dinnick, Discussion on Anaesthesia for Obstetrics an evaluation of general and regional methods
DOI : 10.1097/00132586-195812000-00019

, Proc R Soc Med, vol.50, issue.8, pp.547-56, 1957.

J. Thomas, De l'asthme essentiel : son traitement, Imprimerie Le Bigot frères, 1901.

J. Kamei, T. Hukuhara, and Y. Kasuya, Dopaminergic control of the cough reflex as demonstrated by the effects of apomorphine, Eur J Pharmacol, vol.141, issue.3, pp.511-514, 1987.

A. M. Rosebrugh, A valuable discovery-a new hypnotic, Can Practitioner Rev, vol.33, pp.669-70, 1908.

M. J. Raymond, The treatment of addiction by aversion conditioning with apomorphine, Behav ResTher

H. T. Pershing, Mental therapeutics and the need of psychology in the medical curriculum, JAMA, vol.39, issue.10, pp.551-554, 1902.

H. Feldmann, The ambulatory treatment of alcoholic addicts: a study of 250 cases, Br J Addict Alcohol Other Drugs, vol.55, issue.2, pp.121-129, 1959.

F. Lemere, Aversion treatment of alcoholism: some reminiscences, Br J Addict, vol.82, issue.3, pp.257-265, 1987.

J. Wadstein, H. Ohlin, and P. Stenberg, Effects of apomorphine and apomorphine-L-dopa-carbidopa on alcohol post-intoxication symptoms, Drug Alcohol Depend, vol.3, issue.4, pp.281-288, 1978.

S. B. Jensen, C. B. Christoffersen, and A. Noerregaard, Apomorphine in outpatient treatment of alcohol intoxication and abstinence: a double-blind study, Br J Addict, vol.72, pp.325-355, 1977.

G. Stern, A case of excessive smoking. London: London Hospital Gazette, pp.144-149, 1957.

B. James, Case of homosexuality treated by aversion therapy, Br Med J, vol.1, issue.5280, pp.768-70, 1962.
DOI : 10.1136/bmj.1.5280.768

N. Mcconaghy, Subjective and penile plethysmograph responses following aversion-relief and apomorphine aversion therapy for homosexual impulses, Br J Psychiatry, vol.115, issue.523, pp.723-753, 1969.

C. J. Douglas, Alcoholism. N Y Med J, vol.70, pp.626-634, 1899.

F. Hare, On alcoholism, its clinical aspects and treatment. London: JA Churchill, 1912.

E. Schlatter and S. Lal, Treatment of alcoholism with Dent's oral apomorphine method, Q J Stud Alcohol, vol.33, issue.2, pp.430-436, 1972.

S. Lal, . De, and C. E. Vega, Apomorphine and psychopathology, JNNP, vol.38, pp.722-728, 1975.

P. R. Vessie, Scopolamin-apomorphia amnesia in psychiatry, Curr Res Anesth Analg, vol.4, issue.3, pp.170-81, 1925.

W. R. Gowers, Epilepsy and other chronic convulsive diseases: their causes, symptoms and treatment, 1881.

M. Bouzol, Relation d'une e ´pidémie a ` phénomènes hystéro-choréiques observées a ` Albon (Ardèche) en 1882. Mémoires et comptes-rendus de la Société des Sciences Médicales de Lyon, tome XXIV, pp.177-199, 1884.

J. Laurencin, Effets thérapeutiques du chlorhydrate d'apomorphine en injections sous-cutanées dans l'hystéro-e ´pilepsie, Lyon Méd, vol.47, pp.315-336, 1884.

C. Burgat, Etude de deux cas d'hystéro-e ´pilepsie. Lyon: Imprimerie Nouvelle, vol.1884

H. Sainsbury, Apomorphine hydrochlorate: its use in mental affections, 1903.

R. C. Smith, C. A. Tamminga, J. Haraszti, G. N. Pnadey, and J. M. Davis, Effects of dopamine agonists in tardive dyskinesia, Am J Psychiatry, vol.134, issue.7, pp.763-771, 1977.

C. A. Tamminga, M. H. Schaffer, R. C. Smith, and J. M. Davis, Schizophrenic symptoms improve with apomorphine, Science, vol.200, issue.4341, pp.567-575, 1978.

B. B. Hershenson and E. R. Brubaker, Scopolamine and apomorphine in labor, Am J Obstet Gynecol, vol.53, issue.6, p.980, 1947.

H. F. Sharpley, Scopolamine in obstetrics; use in rapid births, premature births, and cesarean sections; control of restlessness with apomorphine in full term deliveries, Obstet Gynecol Surv, vol.7, issue.3, pp.332-336, 1952.

R. R. White, The use of apomorphine with scopolamine in labor, Am J Obstet Gynecol, vol.64, issue.1, pp.91-100, 1952.

E. K. Schlatter, Treatment of alcoholics with apomorphine using Dent's method; a preliminary study. Montreal: Quebec Psychopharmacological Association, 1966.

A. Benassi-benelli, F. Ferrari, and B. P. Quarantotti, Penile erection induced by apomorphine and N-n-propyl-norapomorphine in rats, Arch Int Pharmacodyn Ther, vol.242, issue.2, pp.241-248, 1979.

S. Lal, D. Ackman, J. X. Thavundayil, M. E. Kiely, and P. Etienne, Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects, Prog Neuropsychopharmacol Biol Psychiatry, vol.8, issue.4-6, pp.695-704, 1984.

S. Lal, E. Laryea, J. X. Thavundayil, N. P. Nair, J. Negrete et al., Apomorphine-induced penile tumescence in impotence patients-preliminary findings, Prog Neuropsychopharmacol Biol Psychiatry, vol.11, pp.235-277, 1987.

A. Morales, Apomorphine to Uprima: the development of a practical erectogenic drug: a personal perspective, Int J Impot Res, vol.13, issue.3, pp.29-34, 2001.

J. P. Heaton, A. Morales, M. A. Adams, B. Johnston, and R. El-rashidy, Recovery of erectile function by the oral administration of apomorphine, Urology, vol.45, issue.2, pp.200-206, 1995.

A. Bechara, M. V. Bertolino, A. Casabé, and N. Fredotovich, A doubleblind randomized placebo control study comparing the objective and subjective changes in female sexual response using sublingual apomorphine, J Sex Med, vol.1, issue.2, pp.209-223, 2004.

S. Caruso, C. Agnello, G. Intelisano, M. Farina, D. Mari et al., Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder, Urology, vol.63, issue.5, pp.955-964, 2004.

T. Tarcan, M. B. Siroky, K. Park, I. Goldstein, and K. M. Azadzoi, Systemic administration of apomorphine improves the hemodynamic mechanism of clitoral and vaginal engorgement in the rabbit, Int J Impot Res, vol.12, issue.4, pp.235-275, 2000.

R. Hamburger-bar and H. Rigter, Apomorphine: facilitation of sexual behaviour in female rats, Eur J Pharmacol, vol.32, issue.02, pp.357-60, 1975.

E. Weill, De l'apomorphine dans certains troubles nerveux, Lyon Med, vol.47, pp.411-419, 1884.

E. Vallender, J Nerv Mental Disease, vol.14, issue.1, p.190, 1877.

E. S. Tolosa and S. B. Sparber, Apomorphine in Huntington's chorea: clinical observations and theoretical considerations, Life Sci, vol.15, issue.7, pp.1371-80, 1974.

G. U. Corsini, P. L. Onali, and C. Masala, Apomorphine hydrochloride-induced improvement in huntington's chorea: stimulation of dopamine receptor, Arch Neurol, vol.35, issue.1, pp.27-30, 1978.

A. Albanese, E. Cassetta, D. Carretta, A. R. Bentivoglio, and P. Tonali, Acute challenge with apomorphine in Huntington's disease: a double-blind study, Clin Neuropharmacol, vol.18, issue.5, pp.427-461, 1995.

C. Vitale, S. Marconi, D. Maio, L. , D. Michele et al., Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: a double blind, randomized cross-over trial, Mov Disord, vol.22, issue.16, pp.2359-64, 2007.

M. Feinberg and B. J. Carroll, Effects of dopamine agonists and antagonists in Tourette's disease, Arch Gen Psychiatry, vol.36, issue.9, pp.979-85, 1979.

S. Lal, Clinical studies with apomorphine, Apomorphine and others dopaminomimetics, pp.1-11, 1981.

E. S. Tolosa, Modification of tardive dyskinesia and spasmodic torticollis by apomorphine. Possible role of dopamine autoreceptors, Arch Neurol, vol.35, issue.7, pp.459-62, 1978.

L. F. Quesney, F. Andermann, S. Lal, and S. Peelevic, Transient abolition of generalized photosensitive epileptic discharge in humans by apomorphine, a dopamine-receptor agonist, Neurology, vol.30, issue.11, pp.1169-74, 1980.

G. G. Tribl, T. Sycha, N. Kotzailias, J. Zeitlhofer, and E. Auff, Apomorphine in idiopathic restless legs syndrome: an exploratory study, J Neurol Neurosurg Psychiatry, vol.76, issue.2, pp.181-186, 2005.

I. Reuter, C. M. Ellis, R. Chaudhuri, and K. , Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome, Acta Neurol Scand, vol.100, issue.3, pp.163-170, 1999.

T. Tings, G. Stiens, W. Paulus, C. Trenkwalder, and S. Happe, Treatment of restless legs syndrome with subcutaneous apomorphine in a patient with short bowel syndrome, J Neurol, vol.252, issue.3, pp.361-364, 2005.

G. C. Cotzias, M. H. Van-woert, and L. M. Schiffer, Aromatic amino acids and modification of parkinsonism, N Engl J Med, vol.276, issue.7, pp.374-383, 1967.
DOI : 10.1056/nejm196702162760703

S. E. Düby, G. C. Cotzias, P. S. Papavasiliou, and W. H. Lawrence, Injected apomorphine and orally administered levodopa in Parkinsonism, Arch Neurol, vol.27, issue.6, pp.474-80, 1972.

J. Justin-besançon and C. Laville, Action antiémétique du métoclopramide vis-a `-vis de l'apomorphine et de l'hydergine, C R Soc Biol (Paris), vol.158, pp.723-730, 1964.

G. U. Corsini, D. Zompo, M. Cianchetti, and C. , Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in parkinsonism, Psychopharmacology, vol.47, p.169, 1976.

G. U. Corsini, D. Zompo, M. Gessa, G. L. Mangoni, and A. , Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease, Lancet, vol.1, issue.8123, pp.954-960, 1979.

C. Stibe, A. Lees, and G. Stern, Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctutations, The Lancet, vol.329, issue.8537, p.871, 1987.

T. Henriksen, Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians, Neurodegener Dis Manag, vol.4, issue.3, pp.271-82, 2014.
DOI : 10.2217/nmt.14.17

P. Martinez-martin, P. Reddy, R. Katzenschlager, A. Antonini, A. Todorova et al., EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease, Mov Disord, vol.30, issue.4, pp.510-516, 2014.

S. Drapier, A. Eusebio, B. Degos, M. Vérin, F. Durif et al., Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study, J Neurol, vol.263, issue.6, pp.1111-1120, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01301510

, , 2016.

R. Katzenschlager, W. Poewe, O. Rascol, C. Trenkwalder, G. Deuschl et al., Double-blind, randomized, placebo-controlled, Phase III study (TOLEDO) to evaluate the efficacy of apomorphine subcutaneous infusion in reducing OFF time in Parkinson's disease patients with motor fluctuations not well controlled on optimized conventional treatment

, Mov Disord, vol.32, issue.2, 2017.

N. Titova and K. R. Chaudhuri, Apomorphine therapy in Parkinson's and future directions, Parkinsonism Relat Disord, vol.33, issue.1, pp.56-60, 2016.

N. Borkar, H. Mu, and R. Holm, Challenges trends in apomorphine drug demivery systems for the treatment of Parkinson's disease

. Asian and . Sci, , 2017.

N. Titova, C. Padmakumar, S. Lewis, and K. R. Chaudhuri, Parkinson's: a syndrome rather than a disease?, J Neural Transm, vol.124, issue.8, pp.907-921, 2016.

K. A. Brennan and R. W. Genever, Managing Parkinson's disease during surgery, BMJ, vol.341, 2010.

A. M. De-campos, L. Braz, P. Linhares, and M. J. Rosas, Deep brain stimulation for Parkinson's disease: subcutaneous apomorphine as an alternative for patients unable to tolerate surgery under local anesthesia, J Neurol Sci, vol.15, issue.378, pp.137-146, 2017.

E. Broussolle, M. H. Marion, and P. Pollak, Continuous subcutaneous apomorphine as replacement for levodopa in severe parkinsonian patients after surgery, Lancet, vol.340, issue.8823, pp.859-60, 1992.

N. Gálvez-jiménez and A. E. Lang, Perioperative problems in Parkinson's disease and their management: apomorphine with rectal domperidone, Can J Neurol Sci, vol.23, issue.3, pp.198-203, 1996.

J. C. Sharma, L. Macnamara, M. Hasoon, and M. Vassallo, Diagnostic and therapeutic value of apomorphine in Parkinsonian patients, Int J Clin Pract, vol.58, issue.11, pp.1028-1060, 2004.

I. Schlesinger, I. Erikh, and M. Zaaroor, Dopamine agonist withdrawal syndrome: the apomorphine solution, Arch Neurol, vol.67, issue.9, pp.1155-1161, 2010.

,

P. J. Slotty, C. Wille, T. M. Kinfe, and J. Vesper, Continuous perioperative apomorphine in deep brain stimulation surgery for Parkinson's disease, Br J Neurosurg, vol.28, issue.3, pp.378-82, 2013.

F. Dewhurst, M. Lee, and B. Wood, The pragmatic use of apomorphine at the end of life, Palliat Med, vol.23, issue.8, pp.777-786, 2009.

U. Bonuccelli, P. Piccini, G. U. Corsini, and A. Muratorio, Apomorphine in malignant syndrome due to levodopa withdrawal, Ital J Neurol Sci, vol.13, issue.2, pp.169-70, 1992.

M. Rosa-grilo, M. A. Qamar, A. Evans, and K. R. Chaudhuri, The efficacy of apomorphine-a non-motor perspective, Parkinsonism Relat Disord, vol.33, issue.1, pp.28-35, 2016.

F. Tison, L. Wiart, M. Guatterie, N. Fouillet, V. Lozano et al., Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease, Mov Disord, vol.11, issue.6, pp.729-761, 1996.

P. C. Hunter, J. Crameri, S. Austin, M. C. Woodward, and A. J. Hughes, Response of parkinsonian swallowing dysfunction to dopaminergic stimulation, J Neurol Neurosurg Psychiatry, vol.63, issue.5, pp.579-83, 1997.

L. L. Edwards, E. M. Quigley, R. K. Harned, R. Hofman, and R. F. Pfeiffer, Defecatory function in Parkinson's disease: response to apomorphine, Ann Neurol, vol.33, issue.5, pp.490-493, 1993.

T. J. Christmas, P. A. Kempster, C. R. Chapple, J. P. Frankel, A. J. Lees et al., Role of subcutaneous apomorphine in parkinsonian voiding dysfunction, Lancet, vol.2, pp.1451-1454, 1988.

G. Bronner and D. B. Vodu?ek, Management of sexual dysfunction in Parkinson's disease, Ther Adv Neurol Disord, vol.4, issue.6, pp.375-83, 2011.

G. Fernández-pajarín, A. Sesar, B. Ares, and A. Castro, Evaluating the efficacy of nocturnal continuous subcutaneous apomorphine infusion in sleep disorders in advanced parkinson's disease: the APO-NIGHT study, J Parkinsons Dis, vol.6, issue.4, pp.787-92, 2016.

R. Shaltiel-karyo, Y. Tsarfati, E. Zawoznik, I. Weinstock, M. Nemas et al., ND0701: A novel safe concentrated apomorphine formulation for continuous subcutaneous administration via a patch pump (P4.006), Neurology, vol.88, pp.4-006, 2017.

R. W. Borgemeester, M. Drent, and T. Van-laar, Motor and non-motor outcomes of continuous apomorphine infusion in 125

, Parkinson's disease patients, Parkinsonism Relat Disord, vol.23, pp.17-22, 2016.

R. W. Borgemeester, A. J. Lees, and T. Van-laar, Parkinson's disease, visual hallucinations and apomorphine: a review of the available evidence, Parkinsonism Relat Disord, vol.27, pp.35-40, 2016.

R. Borgemeester and T. Van-laar, Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: a retrospective long-term follow-up study, Parkinsonism Relat Disord, vol.45, pp.33-41, 2017.

L. Geerligs, A. M. Meppelink, W. H. Brouwer, and T. Van-laar, The effects of apomorphine on visual perception in patients with Parkinson disease and visual hallucinations: a pilot study, Clin Neuropharmacol, vol.32, issue.5, pp.266-274, 2009.

A. J. Yarnall, T. Lashley, H. Ling, A. J. Lees, S. Y. Coleman et al., Apomorphine: a potential modifier of amyloid deposition in Parkinson's disease?, Mov Disord, vol.31, issue.5, pp.668-75, 2015.

M. A. Cousin, J. O. Ebbert, A. R. Wiinamaki, M. D. Urban, D. P. Argue et al., Larval zebrafish model for FDA-approved drug repositioning for tobacco dependence treatment, PLoS ONE, vol.9, issue.3, p.90467, 2014.